During Friday’s Current trade, Shares of Century Aluminum Co (NASDAQ:CENX), gain 3.12% to $6.04.
Century Aluminum Company ( CENX) stated a net loss of $33.9 million ($0.39 per common share) for the second quarter of 2015. Results comprise a $30.9 million impairment charge ($0.35 per common share) related to the permanent closure of our Ravenswood smelter and a $25.7 million charge ($0.30 per common share) for lower of cost or market inventory adjustments. Results were also negatively influenced by $11.7 million ($0.13 per common share) in costs related to the labor disruption at our Hawesville smelter. Lastly, results comprise a $10.3 million ($0.12 per common share) unrealized gain on the fair value of contingent consideration related to the acquisition of the remaining 50.3% interest of Mt. Holly. After consideration of these items, the company stated adjusted net income of $24.1 million and adjusted earnings per share of $0.25.
For the second quarter of 2014, Century stated net income of $20.3 million ($0.21 per common share). Results were negatively influenced by a charge of $0.5 million ($0.01 per common share) for the finalization of a legal settlement.
Sales for the second quarter of 2015 were $523.5 million contrast with $458.3 million for the second quarter of 2014. Shipments of primary aluminum for the second quarter of 2015 were 233,950 tonnes contrast with 216,044 tonnes shipped in the second quarter of 2014.
Century Aluminum Company, together with its auxiliaries, produces primary aluminum in the United States and Iceland. It produces standard grade and value-added primary aluminum products; and carbon products, such as anodes and cathodes. The company was founded in 1995 and is headquartered in Chicago, Illinois.
Shares of Vereit Inc (NYSE:VER), declined -0.46% to $8.59, during its current trading session.
VEREIT, Inc. (VER) declared its operating results for the three months ended June 30, 2015, details on its business plan and enhancements to its corporate governance.
Second Quarter 2015 Merged Financial Results
Revenue
Merged revenue for the quarter ended June 30, 2015 raised $11.5 million to $393.7 million as contrast to revenue of $382.2 million for the same quarter in 2014.
Net Loss
Merged net loss for the quarter ended June 30, 2015 raised $52.1 million to $(108.7) million as contrast to a net loss of $(56.6) million for the same quarter in 2014.
Normalized EBITDA
Merged normalized EBITDA for the quarter ended June 30, 2015 raised $17.6 million to $309.3 million as contrast to normalized EBITDA of $291.7 million for the same quarter in 2014.
VEREIT, Inc. is a publicly owned real estate investment trust. It owns and acquires single tenant, freestanding commercial real estate that is net leased on a medium-term basis, primarily to investment grade credit rated and other creditworthy tenants. The company principally invests in retail and office properties. It was formerly known as American Realty Capital Properties, Inc. VEREIT, Inc. was founded in 2010 and is based in Phoenix, Arizona.
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), during its Friday’s current trading session decreased -3.70% to $9.90.
ZIOPHARM Oncology, Inc. (ZIOP) declared financial results for the second quarter ended June 30, 2015, and offered an update on the company’s recent activities.
Recent Highlights
Ad-RTS-hIL-12
Ad-RTS-hIL-12 is a gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response, using the RheoSwitch Therapeutic System(R) (RTS(R)) gene switch. In April 2015, ZIOPHARM declared the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 and veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. In May 2015, the Company declared the initiation of a multi-center Phase 1 study of Ad-RTS-hIL-12 and veledimex in patients with recurrent or progressive glioblastoma multiforme, a form of brain cancer.
Both gene therapy trials, which are being conducted at leading centers across the U.S., are presently open and accruing patients. The Company anticipates that early results from each study will be presented at scientific meetings proceeding to year end.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability. The company is also developing programs in various stages of development together with Intrexon Corporation’s RheoSwitch Therapeutic System(r) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index.
Finally, Statoil ASA(ADR)(NYSE:STO), decreased -1.04%, to $16.12.
The nomination committee in Statoil (STO) recommends that the company’s corporate assembly elects Wenche Agerup as a new member of Statoil’s board of directors.
The nomination committee in Statoil recommends that Wenche Agerup is elected as new member of the board. Catherine Hughes withdrew from the Statoil board with effect from 19 April 2015. The nomination committee’s search for a new, female board member as a replacement for Hughes is now finalised, and the nomination committee proposes that a supplementary election to the board is held in the corporate assembly meeting 20 August 2015.
Statoil ASA, an energy company, engages in the exploration, production, transportation, refining, and marketing of petroleum and petroleum-derived products in Norway and internationally. The company operates through Development and Production Norway; Development and Production International; Marketing, Processing and Renewable Energy; and Other segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
